Edgar G. Engleman
From Wikipedia, the free encyclopedia
Edgar G. Engleman (born 1945) is an American pathologist and physician-scientist who researches cancer immunology. He is a professor of pathology and of medicine (immunology and rheumatology) at Stanford University School of Medicine.[1] He is also a co-founder of Vivo Capital, a Healthcare Investment firm.[2]
Engleman earned a B.A., magna cum laude, from Harvard College in 1967.[3] He completed a M.D. from the Columbia University College of Physicians & Surgeons in 1971.[3] He was an intern in medicine at Moffitt Hospital, University of California, San Francisco from 1971 to 1972.[3] This was followed by a residency at the University of California Hospital in San Francisco from 1972 to 1973.[3] Engleman was a research associate in the laboratory of biochemistry under Earl Reece Stadtman at the National Heart, Lung, and Blood Institute from 1973 to 1976.[3] He was a postdoctoral fellow in immunogenetics and rheumatology under Hugh McDevitt at the Stanford University School of Medicine from 1976 to 1978.[3]
After studying immunology as a post-doctoral fellow, in 1978, Engleman became a faculty member in the department of pathology.[4][3] He was an assistant professor of pathology and medicine.[3] He was promoted to professor with tenure in 1990. The same year, he won an NIH MERIT award.[3]
At Stanford University, Engleman has been researching the immune system and its role in diseases for forty years.[4] Since 1980 he has been the founding director of the Stanford Blood Center,[1] which allowed him to access immune cells (or white blood cells) for his immunological research.[4] He moved into the field of cancer biology.[4] He directs the Engleman Lab, focusing on studying the cellular immunology of cancer.[5] His research was the basis for the first active immunotherapeutic strategy for cancer to be approved by the FDA in 2010.[6]
Selected works
- Engleman, Edgar G., ed. (1980). Genetic Control of the Human Immune Response: Proceedings a Conference Sponsored by the Kroc Foundation, Santa Ynes Valley, California 28 Jan-1 Feb 1980. Vol. 152. Rockefeller University Press.
- Engleman, Edgar G.; Foung, Steven K. H.; Larrick, James W.; Raubitschek, Andrew A., eds. (1985). Human Hybridomas and Monoclonal Antibodies. Boston, MA: Springer US. doi:10.1007/978-1-4684-4949-5. ISBN 978-1-4684-4951-8. S2CID 3005405.
References
- 1 2 "Edgar Engleman". Stanford Medicine CAP Profiles. Retrieved 2023-04-18.
- ↑ "Fireside Chat：Entrepreneuership" (PDF). Taiwan Biomedical Innovation Association. November 19, 2022.
- 1 2 3 4 5 6 7 8 9 Engleman, Edgar G. "Curriculum Vitae". Stanford University School of Medicine. Retrieved 2023-04-16.
- 1 2 3 4 "Dr. Edgar Engleman: Advancing the Field of Cancer Immunology - NCI". www.cancer.gov. 2022-11-21. Retrieved 2023-04-16.
This article incorporates text from this source, which is in the public domain. - ↑ "Engleman Lab". Engleman Lab. Retrieved 2023-04-18.
- ↑ "Dr. Edgar Engleman". Stanford Blood Center. Retrieved 2023-04-18.
This article incorporates public domain material from websites or documents of the National Institutes of Health.| International | |
|---|---|
| National | |
| Academics | |
| Other | |
